Huntington Disease - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Huntington Disease Emerging Therapy and TPP Insights

Thelansis's "Huntington Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Huntington's Disease Overview

Huntington's disease (HD) is a rare, progressive, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, resulting in the production of toxic mutant huntingtin (mHTT) protein. The disease is characterized by progressive degeneration of neurons, particularly within the striatum and cerebral cortex, leading to worsening motor dysfunction, cognitive decline, and psychiatric disturbances. Genetic anticipation is commonly observed, with successive generations often experiencing earlier disease onset and increased severity.

Clinically, HD presents with a triad of motor, cognitive, and psychiatric symptoms. Early disease is typically associated with hyperkinetic movements such as chorea, while advanced stages progress toward rigidity, dystonia, impaired coordination, and severe functional decline. Cognitive impairment gradually evolves into subcortical dementia, accompanied by psychiatric manifestations including depression, apathy, anxiety, irritability, and impulsive behavior, significantly impacting patient quality of life and caregiver burden.

Currently, no curative or disease-modifying therapies are approved to halt or reverse disease progression, and management remains primarily symptomatic and supportive. VMAT2 inhibitors, including tetrabenazine and deutetrabenazine, are commonly used to manage chorea, while psychiatric symptoms are addressed through antidepressants, antipsychotics, and multidisciplinary supportive care. Increasing research focus on gene-silencing therapies, RNA-targeted approaches, and disease-modifying strategies is expected to reshape the future treatment landscape for HD.

Key Highlights

• In the USA, diagnosed Huntington's disease cases are projected to increase from approximately 39,486 to 42,458, reflecting a gradually increasing diagnosed patient population.
• HD remains a high unmet need neurodegenerative disorder due to the absence of approved disease-modifying therapies.
• Motor dysfunction, cognitive decline, and psychiatric complications continue to contribute substantially to disease burden and caregiver dependency.
• Emerging gene-targeting and RNA-based therapies are driving significant research and clinical development interest in HD treatment.
• Increasing awareness and improved genetic testing are supporting earlier diagnosis and patient identification.

Market Overview

• The Germany Huntington's disease market is projected to grow from approximately $42 MN to $130 MN, reflecting significant market expansion.
• Market growth is supported by:
• Increasing adoption of symptomatic therapies and multidisciplinary disease management
• Advancing development of gene-silencing and disease-modifying therapeutic approaches
• Rising diagnostic awareness and improved access to genetic testing are contributing to patient pool expansion.
• Future market growth will largely depend on successful commercialization of next-generation disease-modifying therapies targeting mutant huntingtin protein pathways.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• SOM Innovation Biotech SA
• Neurocrine Biosciences
• Skyhawk Therapeutics, Inc.
• Sarepta Therapeutics, Inc.
• Hoffmann-La Roche
• Alnylam Pharmaceuticals
• Supernus Pharmaceuticals, Inc.
• UniQure Biopharma B.V.
• Novartis Pharmaceuticals
• Prilenia
• ExoRNA Bioscience
• Medibiofarma S.L.
• Wave Life Sciences Ltd.
• PTC Therapeutics